AIMZ Investment Advisors LLC Sells 1,050 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

AIMZ Investment Advisors LLC cut its position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 0.5% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 226,574 shares of the company’s stock after selling 1,050 shares during the period. Teva Pharmaceutical Industries makes up 1.7% of AIMZ Investment Advisors LLC’s portfolio, making the stock its 14th largest holding. AIMZ Investment Advisors LLC’s holdings in Teva Pharmaceutical Industries were worth $4,994,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in the company. Smithfield Trust Co increased its stake in Teva Pharmaceutical Industries by 55.7% in the third quarter. Smithfield Trust Co now owns 2,739 shares of the company’s stock worth $50,000 after purchasing an additional 980 shares during the period. Wilmington Savings Fund Society FSB purchased a new stake in shares of Teva Pharmaceutical Industries during the third quarter valued at $50,000. Venturi Wealth Management LLC bought a new position in shares of Teva Pharmaceutical Industries in the third quarter worth about $60,000. Ameliora Wealth Management Ltd. purchased a new position in Teva Pharmaceutical Industries in the 4th quarter worth about $66,000. Finally, Farther Finance Advisors LLC lifted its holdings in Teva Pharmaceutical Industries by 273.5% during the 3rd quarter. Farther Finance Advisors LLC now owns 4,538 shares of the company’s stock valued at $82,000 after buying an additional 3,323 shares in the last quarter. 54.05% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Teva Pharmaceutical Industries news, Director Roberto Mignone sold 286,000 shares of the business’s stock in a transaction dated Friday, December 20th. The stock was sold at an average price of $22.01, for a total transaction of $6,294,860.00. Following the sale, the director now owns 695,000 shares in the company, valued at approximately $15,296,950. The trade was a 29.15 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.55% of the stock is currently owned by company insiders.

Teva Pharmaceutical Industries Stock Performance

Shares of TEVA stock opened at $16.32 on Friday. Teva Pharmaceutical Industries Limited has a 12-month low of $12.51 and a 12-month high of $22.80. The business’s fifty day simple moving average is $19.75 and its 200-day simple moving average is $18.48. The company has a current ratio of 0.98, a quick ratio of 0.75 and a debt-to-equity ratio of 2.97. The company has a market cap of $18.49 billion, a PE ratio of -11.26, a PEG ratio of 1.44 and a beta of 0.71.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its earnings results on Wednesday, January 29th. The company reported $0.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. Analysts expect that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current fiscal year.

Analysts Set New Price Targets

TEVA has been the topic of a number of research reports. StockNews.com lowered shares of Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, December 18th. Barclays dropped their target price on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating on the stock in a report on Thursday, January 30th. UBS Group lowered their price target on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating for the company in a research report on Thursday, January 30th. Finally, Piper Sandler increased their price objective on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an “overweight” rating in a research note on Friday, January 17th. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat.com, Teva Pharmaceutical Industries currently has a consensus rating of “Moderate Buy” and an average price target of $23.57.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.